Fezolinetant

非唑奈坦

Report date: 2026/05/21 20:00:22
NME

Base Information

Drug NameFezolinetant
Drug Alias Name非佐奈坦EzolinetantumVEOZAHESN-364A2693 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeurokinin 3 receptor antagonists
TargetsNeurokinin 3 receptor
Therapy Area/IndicationsVasomotor symptomMenopausal symptomsHot Flashes +[9] 
Global Approved IndicationsVasomotor symptomHot Flashes
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/05/12
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesOgeda SA
China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma Us IncAstellas (China) Investment Co LtdChinese University Of Hong Kong (Cuhk) +[11] 
Inactive CompaniesOgeda SAUniversity Of Michigan Rogel Cancer Center
Active IndicationsVasomotor symptomMenopausal symptomsHot Flashes +[6] 
Inactive IndicationsCardiovascular DiseasesHepatic InsufficiencyCarcinoma, Ductal, Breast

Other Information

ATC CodeG02CX06
Related LinksDrugBankKEGG